autologous CD19 chimeric antigen receptor T cells

Autologous CD19 chimeric antigen receptor (CAR) T cells are an investigative cellular immunotherapy developed by Universitaetsklinikum Erlangen for the treatment of severe, steroid-refractory chronic graft-versus-host disease (cGvHD) and various systemic autoimmune diseases. The therapy involves the ex vivo genetic modification of a patient's own T cells using a lentiviral vector to express a second-generation CAR (typically featuring a 4-1BB costimulatory domain) that targets the CD19 antigen on B cells. Upon re-infusion, these engineered T cells mediate the systemic depletion of B cells, which are key drivers of the inflammatory and fibrotic processes in cGvHD and autoantibody production in diseases like systemic lupus erythematosus (SLE). This approach aims to achieve a "reset" of the immune system, potentially allowing for the re-establishment of immune tolerance and long-term drug-free remission.

Other names

CD19 CAR-T cellsCD-19 CAR-T cellsCD 19 CAR-T cellsautologous CD19-targeted CAR T cells